サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1791666

内視鏡的逆行性胆管膵管造影法の世界市場

Endoscopic Retrograde Cholangiopancreatography

出版日
ページ情報
英文 183 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.42円
内視鏡的逆行性胆管膵管造影法の世界市場
出版日: 2025年08月15日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 183 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

内視鏡的逆行性胆管膵管造影法の世界市場は2030年までに75億米ドルに達する見込み

2024年に47億米ドルと推定される内視鏡的逆行性胆管膵管造影法の世界市場は、分析期間2024-2030年にCAGR 8.3％で成長し、2030年には75億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである内視鏡は、CAGR 9.6％を記録し、分析期間終了時には29億米ドルに達すると予測されます。内視鏡治療機器セグメントの成長率は、分析期間でCAGR 8.7％と推定されます。

米国市場は12億米ドル、中国はCAGR 8.0％で成長予測

米国の内視鏡的逆行性胆管膵管造影法市場は2024年に12億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに12億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは8.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ7.8％と6.9％と予測されています。欧州では、ドイツがCAGR約6.5％で成長すると予測されています。

世界の内視鏡的逆行性胆管膵管造影法（ERCP）市場- 主要動向と促進要因のまとめ

なぜERCPは消化器・肝胆膵医療において重要な手技なのか？

内視鏡的逆行性胆管膵管造影法（ERCP）は、胆石、胆管狭窄、膵腫瘍、慢性膵炎などの胆道・膵臓疾患の診断・治療に用いられる低侵襲の内視鏡技術です。この手技は内視鏡検査と透視検査を組み合わせて、胆道や膵管に影響を及ぼす病態を可視化し治療するもので、開腹手術の必要性を低減します。

胆嚢疾患、膵臓がん、胆管閉塞の有病率の上昇と、肝胆道系疾患に罹患しやすい老年人口の増加が、ERCP手技の需要を大幅に増加させています。さらに、自己拡張型金属ステント（SEMS）、括約筋切開器、バルーン拡張器などのERCP付属品の進歩により、手技の成功率と患者の転帰が改善されています。病院や専門消化器センターが内視鏡機能を拡充するにつれ、ERCPの採用はさらに拡大すると予想されます。

ERCP技術の最新イノベーションとは？

ERCPの最近の進歩は、可視化の強化、合併症の減少、治療精度の向上に重点を置いています。高精細デジタル透視法とAI支援胆管造影解釈の開発により、小さな病変や胆管異常の検出が向上しています。最先端の胆管鏡プラットフォームであるSpyGlass Direct Visualization Systemsは、胆管や膵管のリアルタイムイメージングを可能にし、標的を絞った生検採取や精密ガイド下での結石除去を可能にします。

生分解性胆道ステントの導入により、再手術の必要性が減少し、患者の利便性が向上し、ヘルスケアコストが削減されました。さらに、手技の精度を高め、術者の疲労を軽減し、複雑な胆道・膵臓疾患の治療成績を向上させるために、ロボット支援ERCP技術が研究されています。ERCPが進化を続ける中、機械学習ベースの予測分析とAIガイド下内視鏡ナビゲーションの統合により、手技の精度と安全性が高まると期待されています。

何がERCP市場の成長を牽引しているのか？

ERCP市場の成長は、消化管疾患の増加、低侵襲技術の採用の増加、内視鏡イメージングおよび介入ツールの進歩によってもたらされます。胆道および膵臓疾患に対する非外科的治療への嗜好の高まりが、高度な内視鏡センターの拡大と相まって、市場の需要を促進しています。さらに、膵臓がんの罹患率の上昇と治療的内視鏡処置の必要性の増加がERCPの採用に寄与しています。

次世代ERCP機器、AI搭載胆管鏡プラットフォーム、ロボット支援内視鏡の統合に対する規制認可は、市場成長をさらに加速させると予想されます。継続的な技術の進歩、ヘルスケア投資の増加、専門的な消化器科医療への世界のアクセスの増加により、ERCP市場は今後数年で大幅な拡大が見込まれます。

セグメント

製品（内視鏡、エンドセラピーデバイス、可視化システム、エネルギーデバイス、その他）;手技（胆道括約筋切開術、胆道ステント留置術、胆道拡張術、膵括約筋切開術、膵管ステント留置術、膵管拡張術）;エンドユーザー（病院、外来患者施設）

調査対象企業の例

  • Ambu A/S
  • Ambu Inc.
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Bio-Rad Medisys Pvt. Ltd.
  • Boston Scientific Corporation
  • CONMED Corporation
  • Cook Medical
  • DCC Healthcare（Medi-Globe GmbH）
  • Fujifilm Holdings Corporation
  • HOBBS MEDICAL
  • HOYA Corporation
  • Huger Medical Instrument Co., Ltd
  • Johnson & Johnson
  • KARL STORZ SE & Co. KG
  • Lancetinc Medical
  • LeoMed
  • Medtronic PLC
  • Merit Medical Systems
  • Olympus Corporation

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP30780

Global Endoscopic Retrograde Cholangiopancreatography Market to Reach US$7.5 Billion by 2030

The global market for Endoscopic Retrograde Cholangiopancreatography estimated at US$4.7 Billion in the year 2024, is expected to reach US$7.5 Billion by 2030, growing at a CAGR of 8.3% over the analysis period 2024-2030. Endoscopes, one of the segments analyzed in the report, is expected to record a 9.6% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Endotherapy Devices segment is estimated at 8.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 8.0% CAGR

The Endoscopic Retrograde Cholangiopancreatography market in the U.S. is estimated at US$1.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 8.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.8% and 6.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.5% CAGR.

Global Endoscopic Retrograde Cholangiopancreatography (ERCP) Market - Key Trends & Drivers Summarized

Why Is ERCP a Critical Procedure in Gastrointestinal and Hepatobiliary Medicine?

Endoscopic Retrograde Cholangiopancreatography (ERCP) is a minimally invasive endoscopic technique used for the diagnosis and treatment of biliary and pancreatic disorders, including gallstones, bile duct strictures, pancreatic tumors, and chronic pancreatitis. This procedure combines endoscopy and fluoroscopy to visualize and treat conditions affecting the biliary and pancreatic ducts, reducing the need for open surgical interventions.

The rising prevalence of gallbladder disease, pancreatic cancer, and bile duct obstructions, along with increasing geriatric populations prone to hepatobiliary disorders, has significantly increased the demand for ERCP procedures. Additionally, advancements in ERCP accessories, including self-expanding metal stents (SEMS), sphincterotomes, and balloon dilators, have improved procedural success rates and patient outcomes. As hospitals and specialty gastroenterology centers expand their endoscopic capabilities, ERCP adoption is expected to grow further.

What Are the Latest Innovations in ERCP Technology?

Recent advancements in ERCP have focused on enhancing visualization, reducing complications, and improving therapeutic precision. The development of high-definition digital fluoroscopy and AI-assisted cholangiography interpretation has improved the detection of small lesions and bile duct abnormalities. SpyGlass Direct Visualization Systems, a state-of-the-art cholangioscopy platform, allows real-time imaging of bile and pancreatic ducts, enabling targeted biopsy collection and precision-guided stone removal.

The introduction of biodegradable biliary stents has reduced the need for repeat procedures, improving patient convenience and lowering healthcare costs. Additionally, robot-assisted ERCP techniques are being explored to enhance procedural precision, reduce operator fatigue, and improve outcomes in complex biliary and pancreatic disorders. As ERCP continues to evolve, the integration of machine learning-based predictive analytics and AI-guided endoscopic navigation is expected to enhance procedural accuracy and safety.

What Is Driving the Growth of the ERCP Market?

The growth in the ERCP market is driven by rising gastrointestinal disorders, increased adoption of minimally invasive techniques, and advancements in endoscopic imaging and intervention tools. The growing preference for non-surgical treatments for biliary and pancreatic diseases, combined with the expansion of advanced endoscopy centers, has fueled market demand. Additionally, the rise in pancreatic cancer incidence and the increasing need for therapeutic endoscopic procedures have contributed to ERCP adoption.

Regulatory approvals for next-generation ERCP devices, AI-powered cholangioscopy platforms, and the integration of robotic-assisted endoscopy are expected to further accelerate market growth. With continued technological advancements, rising healthcare investments, and increasing global access to specialized gastroenterology care, the ERCP market is poised for substantial expansion in the coming years.

SCOPE OF STUDY:

The report analyzes the Endoscopic Retrograde Cholangiopancreatography market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices, Others); Procedure (Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation, Pancreatic Sphincterotomy, Pancreatic Duct Stenting, Pancreatic Duct Dilation); End-Use (Hospitals, Outpatient Facilities)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

  • Ambu A/S
  • Ambu Inc.
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Bio-Rad Medisys Pvt. Ltd.
  • Boston Scientific Corporation
  • CONMED Corporation
  • Cook Medical
  • DCC Healthcare (Medi-Globe GmbH)
  • Fujifilm Holdings Corporation
  • HOBBS MEDICAL
  • HOYA Corporation
  • Huger Medical Instrument Co., Ltd
  • Johnson & Johnson
  • KARL STORZ SE & Co. KG
  • Lancetinc Medical
  • LeoMed
  • Medtronic PLC
  • Merit Medical Systems
  • Olympus Corporation

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Endoscopic Retrograde Cholangiopancreatography - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Pancreatic and Biliary Disorders Drives Demand for ERCP Procedures Globally
    • Advancements in ERCP Devices Enhance Procedural Accuracy and Reduce Complication Rates
    • Aging Population and Gallstone-Related Complications Fuel Volume Growth in ERCP Interventions
    • Integration of Fluoroscopy and Digital Imaging Tools Supports Complex ERCP Navigation and Diagnosis
    • Availability of Disposable Duodenoscopes Addresses Contamination Risks and Improves Infection Control
    • Increase in Minimally Invasive Biliary Drainage Techniques Expands Use of ERCP in Non-Surgical Settings
    • Specialty Training Programs and GI Fellowship Expansion Promote Adoption of Advanced ERCP Procedures
    • Growth in Therapeutic ERCP for Stent Placement and Stone Extraction Strengthens Hospital Utilization
    • Hybrid Endoscopic Procedures Combine ERCP With EUS for Improved Visualization and Targeting
    • Coding and Reimbursement Updates Enhance Procedural Profitability for Outpatient ERCP Settings
    • Development of Smart Guidewires and Cannulation Devices Increases Success Rate in Complex ERCP
    • Global Expansion of Endoscopy Suites and Digestive Health Centers Fuels ERCP Procedure Adoption
    • Portable Imaging and AI-Guided ERCP Platforms Enable Better Access in Community and Rural Hospitals
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Endoscopic Retrograde Cholangiopancreatography Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Endoscopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Endoscopes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Endotherapy Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Endotherapy Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Visualization Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Visualization Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Energy Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Energy Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pancreatic Duct Stenting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Pancreatic Duct Stenting by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Pancreatic Duct Dilation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Pancreatic Duct Dilation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Biliary Sphincterotomy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Biliary Sphincterotomy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Biliary Stenting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Biliary Stenting by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Biliary Dilatation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Biliary Dilatation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Pancreatic Sphincterotomy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Pancreatic Sphincterotomy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Outpatient Facilities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Outpatient Facilities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Endoscopic Retrograde Cholangiopancreatography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 30: USA Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 34: USA Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: USA 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030
  • CANADA
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030
  • JAPAN
    • Endoscopic Retrograde Cholangiopancreatography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 42: Japan Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 46: Japan Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Japan 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030
  • CHINA
    • Endoscopic Retrograde Cholangiopancreatography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 48: China Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: China 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 52: China Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: China 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030
  • EUROPE
    • Endoscopic Retrograde Cholangiopancreatography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 58: Europe Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Europe 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 60: Europe Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Europe 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030
  • FRANCE
    • Endoscopic Retrograde Cholangiopancreatography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 64: France Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: France 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 66: France Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: France 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030
  • GERMANY
    • Endoscopic Retrograde Cholangiopancreatography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 70: Germany Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Germany 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 72: Germany Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Germany 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 76: Italy Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Italy 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 78: Italy Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Italy 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030
  • UNITED KINGDOM
    • Endoscopic Retrograde Cholangiopancreatography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 82: UK Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: UK 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 84: UK Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: UK 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 88: Rest of Europe Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of Europe 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 90: Rest of Europe Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of Europe 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Endoscopic Retrograde Cholangiopancreatography Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 94: Asia-Pacific Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Asia-Pacific 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 96: Asia-Pacific Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Asia-Pacific 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Product - Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Product - Percentage Breakdown of Value Sales for Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices and Others for the Years 2025 & 2030
    • TABLE 100: Rest of World Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by Procedure - Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Rest of World 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by Procedure - Percentage Breakdown of Value Sales for Pancreatic Duct Stenting, Pancreatic Duct Dilation, Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation and Pancreatic Sphincterotomy for the Years 2025 & 2030
    • TABLE 102: Rest of World Recent Past, Current & Future Analysis for Endoscopic Retrograde Cholangiopancreatography by End-Use - Hospitals and Outpatient Facilities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Rest of World 6-Year Perspective for Endoscopic Retrograde Cholangiopancreatography by End-Use - Percentage Breakdown of Value Sales for Hospitals and Outpatient Facilities for the Years 2025 & 2030

IV. COMPETITION